Register for free to
view the full innovation profile.
A novel method and class of substrates to measure coagulation activation using whole blood, such as from a finger prick test
About
Background Measuring coagulation activation, including thrombin generation, is useful in a number of clinical conditions Technology Overview McMaster researchers have developed a novel method and class of substrates to do this using whole blood, for instance from a finger prick, using conventional fluorescence equipment. Stage of Development: Proof of Principle available. 14-019
Key Benefits
• Ability to monitor thrombin generation in whole blood. • Detect thrombin generation without a correction of alpha-2-macroglobulin bound thrombin. • This invention allows one to detect for the presence of new oral anticoagulants in whole blood within 15 minutes of a finger-prick, which is a novel, unique and valuable feature. There is a great need to detect NOACs at the point-of-care in endoscopy suites, emergency rooms, dentist’s offices, pre-op settings, cardiologist’s offices and internal medicine or family medicine offices. • Ability to detect presence of direct factor Xa and direct thrombin inhibitors. • Point-of-care test.
Applications
• Generate a point-of-care thrombin generation curve in the absence of anticoagulants in whole blood. Thrombin generation curves are known to be altered in different disease states. • This novel method can be used as a point-of-care test for the presence of novel oral anticoagulants (NOACs), namely rivaroxaban, apixaban, and dabigatran in blood. • Detect disorders of coagulation at point-of-care • Screen for inhibitors of coagulation in whole blood